The document discusses the process of drug discovery and development. It has 5 main stages: drug discovery, pre-clinical testing, clinical trials (phases I-III), regulatory approval, and post-marketing surveillance. Drug discovery involves screening compounds for pharmacological activity through random testing, serendipitous findings, or rational drug design. Pre-clinical testing involves extensive animal studies to evaluate safety, efficacy, and adverse effects. Clinical trials in humans have 3 phases to further assess these factors before regulatory approval and marketing of the drug. Post-approval monitoring continues to study long-term safety and efficacy.
Requirements And Guidelines For Permission To Import / or Manufacture of New Drugs For Sale or To Undertake Clinical Trials
Schedule Y was introduced under the Drugs and Cosmetics Act 1940, to
introduce requirements for countries to get permission for:
Importing
Manufacturing new drugs
Conducting Clinical Trials.
Application for permission
Clinical Trial
Studies in specific population
Post marketing surveillance
Special studies: BA/BE studies
History and Progress of Pharmacovigilance, Significance of Safety Monitoring, Pharmacovigilance in India And International Aspects, WHO International Drug Monitoring Programme, WHO and Regulatory Terminologies of ADR, Evaluation of Medication Safety, Establishing Pharmacovigilance Centres in Hospitals, Industry and National Programmes Related to Pharmacovigilance, Roles and Responsibilities in Pharmacovigilance, International Non-Proprietary Names for Drugs, International Classification of Diseases, Passive and Active Surveillance, Comparative Observational Studies, Targeted Clinical Investigations and Vaccine Safety Surveillance, Aris G Pharmacovigilance, VigiFlow, Statistical Methods for Evaluating Medication Safety Data
FOMAT Medical Research is a site research network specializes in developing clinical. We offer a wide range of solutions for Sponsors, Clinical Contract Organizations (CROs), and Sites throughout the Americas. Visit here- https://www.fomatmedical.com
Requirements And Guidelines For Permission To Import / or Manufacture of New Drugs For Sale or To Undertake Clinical Trials
Schedule Y was introduced under the Drugs and Cosmetics Act 1940, to
introduce requirements for countries to get permission for:
Importing
Manufacturing new drugs
Conducting Clinical Trials.
Application for permission
Clinical Trial
Studies in specific population
Post marketing surveillance
Special studies: BA/BE studies
History and Progress of Pharmacovigilance, Significance of Safety Monitoring, Pharmacovigilance in India And International Aspects, WHO International Drug Monitoring Programme, WHO and Regulatory Terminologies of ADR, Evaluation of Medication Safety, Establishing Pharmacovigilance Centres in Hospitals, Industry and National Programmes Related to Pharmacovigilance, Roles and Responsibilities in Pharmacovigilance, International Non-Proprietary Names for Drugs, International Classification of Diseases, Passive and Active Surveillance, Comparative Observational Studies, Targeted Clinical Investigations and Vaccine Safety Surveillance, Aris G Pharmacovigilance, VigiFlow, Statistical Methods for Evaluating Medication Safety Data
FOMAT Medical Research is a site research network specializes in developing clinical. We offer a wide range of solutions for Sponsors, Clinical Contract Organizations (CROs), and Sites throughout the Americas. Visit here- https://www.fomatmedical.com
IND (Investigational New Drug) industrial perspectiveAYESHA NAZEER
Describing the Industry's/sponsor's/drug manufacturers' perspective of the Investigational New Drug Application (IND) program based on the survey conducted by the Office Of Inspector General (OIG).
Roles and Responsibilities in Clinical Trials of Investigator, Study Coordinator, Sponsor, Monitor, a Contract research organization.
The clinical trial, definition, description, Different types of clinical trials, phases of clinical trial.
The clinical trial study team.
Requirements of the clinical trial study team.
Clinical research team role.
GCP- Good clinical practices.
this slide share will provide information about drug discovery and development.in this, how the drug is discovered and what type of procedures and instructions followed during discovery and development of a new drug and also give limitations of drug discovery and development process.
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
This presentation contain detailed information about the "Regulation Governing Clinical Trials In India,USA and Europe".And about the clinical trails and medical devices regulations in India.
The Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial.
ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH ON HUMAN PARTICIPANTSjyothibhat21
This presentation highlights the regulations on Ethical requirements for conducting clinical research in India. This is the guiding regulation for the Ethics Committees in India.
The viewers are requested to give their feedback on the utility of the presentation.
DRUG DISCOVERY & DEVELOPMENT PROCESS, it's a detail description about how drug is made available in market it's development and discovery of drug The Hole Study is given in This Topic.
IND (Investigational New Drug) industrial perspectiveAYESHA NAZEER
Describing the Industry's/sponsor's/drug manufacturers' perspective of the Investigational New Drug Application (IND) program based on the survey conducted by the Office Of Inspector General (OIG).
Roles and Responsibilities in Clinical Trials of Investigator, Study Coordinator, Sponsor, Monitor, a Contract research organization.
The clinical trial, definition, description, Different types of clinical trials, phases of clinical trial.
The clinical trial study team.
Requirements of the clinical trial study team.
Clinical research team role.
GCP- Good clinical practices.
this slide share will provide information about drug discovery and development.in this, how the drug is discovered and what type of procedures and instructions followed during discovery and development of a new drug and also give limitations of drug discovery and development process.
Concept of Pharmacovigilance, history and development of pharmacovigilance, WHO International drug monitoring programme, Pharmacovigilance programme of India
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
This presentation contain detailed information about the "Regulation Governing Clinical Trials In India,USA and Europe".And about the clinical trails and medical devices regulations in India.
The Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial.
ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH ON HUMAN PARTICIPANTSjyothibhat21
This presentation highlights the regulations on Ethical requirements for conducting clinical research in India. This is the guiding regulation for the Ethics Committees in India.
The viewers are requested to give their feedback on the utility of the presentation.
DRUG DISCOVERY & DEVELOPMENT PROCESS, it's a detail description about how drug is made available in market it's development and discovery of drug The Hole Study is given in This Topic.
introduction to practical pharmacology, various experimental animal uses, CPCSEA guidelines, different phases of clinical trial, pre-clinical trial, important pharmacological definition
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
2. WHAT IS A DRUG?
WHO defines it as any substance or a product that is used or intended to be used
to modify or explore the physiological system or pathological states for the
benefit of the recipient.
New drug is a substance of chemical or biological origin for which adequate data
is not available for the regulatory authorities to judge its efficacy and safety of
the proposed claim.
New drug development is done as per the guidelines laid down by Schedule Y of
DRUGS AND COSMECTIC ACT (10th amendment),2001 which were
amended later in 2005.
3. STAGES IN NEW DRUG DEVELOPMENT
1. DRUG DISCOVERY 2-5 years
2. PRE-CLINICAL PHASE 1.5-2 years
3. CLINICAL TRAIL PHASE 5-7 years
PHASE I
PHASE II
PHASE III
4. REGULATORY APPROVAL 1.5 years
5. RESTRICTED MARKETING Upto 4 years
Post Marketing Surveillance phase
4. “OLD METHODS OF DRUG
DISCOVERY”
Crude plants, animal products, minerals were used to treat disease in India, China
and Egypt.
No study before using them. Agents were selected on the basis of their symbolic
qualities and astrological signs.
Greek physicians used Iron against Weakness.
Horn of Rhinoceros as a potent aphrodisiac.
5. DRUG DEVELOPMENT
Drug development process can be divided into 3 many phases, namely :
1. Drug Discovery Phase : Candidate Molecules are chosen on basis of
Pharmacological properties.
2. Preclinical Phase : Wide range of animal studies are performed.
3. Clinical trial phase : Lead compound is evaluated for efficacy, safety and
adverse effects.
7. DRUG DISCOVERY PHASE
“RANDOM SCREENING”
Blind hitting procedure where new chemicals are subjected to various
Pharmacological screening procedure.
Test include studies on Animal behaviour, Animal models of the disease and on
isolated tissues.
Drugs like Morphine, Atropine & Digitalis were discovered this way.
8. SERENDIPITY
Sometimes, a new use is discovered for an old drug or its side effects find a new
therapeutic application.
Example:
Lignocaine and Phenytoin were later used as antiarrhythmics
Methotrexate used for Psoriasis
Penicillin was also discovered this way.
Cyclophosphamide and Azathioprine used to prevent tissue rejection in kidney
transplant.
9. RATIONALE DRUG DESIGNING
Two basic strategies are used :
Compound centred approach Target centered approach
In Compound Centered approach,
Promising agents can be obtained from natural products.
E.g., Penicillin from Mold penicillum
Paclitaxel derived from Pacific Yew tree.
Cyclosporine obtained from fungus.
10. Lead Optimisation becomes difficult as these natural sources are complex
molecules and are difficult to synthesised.
Compound Centered Drug Designing can be followed for synthetic drug also,
Drug this way can be obtained from structure activity of an already established
drug.
Example:
a) ß-adrenoceptor blocking drugs are based on propranolol structure.
b) Many triptans are based on structure of sumatriptan.
11. TARGET CENTERED APPROACH
Valid Biochemical Molecular Targets
Inhibition of ACE blocks conversion of Angiotensin I to Angiotensin II and
hence lowers Blood pressure.
Hence ACE Inhibitors (Lisinopril, Ramipril) and Angiotensin II receptor
antagonist (Losartan, Telmisartan) are useful antihypertensive.
12. DESIGNING OF A PRODRUG OR ACTIVE METABOLITE
Prodrug – agent that is administered as a precursor of a drug and converted
into active metabolite in the body.
e.g., Levodopa used as a prodrug of Dopamine in the treatment of
parkinsonism.
Active metabolites of certain drugs have also been found to have therapeutic
effect.
e.g., Paracetamol an active metabolite of Phenacetin was introduced as a safe
analgesic this way.
13. After Synthesis or isolation of compounds, purity is ascertained by physico-chemical and
analytical studies.
Stage of LEAD OPTIMISATION
Aim is to identify one or two drug candidates for further investigation
(3-5 years may be spent to come to this stage)
Promising LEAD COMPOUND
Subjected to preclinical evaluation.
Clinical trails follow only when the results of Preclinical evaluations are encouraging.
14. PRECLINICAL EVALUATION PHASE
(ANIMAL STUDIES)
After identifying a Prospective Compound, it is tested on
animals to expose the Pharmacological profile.
Experiments are performed on rodents and then on larger
animal.
As evaluation progresses, only a few out of thousands reach
the stage when administration to humans is considered.
15. OBJECTIVES OF ANIMAL STUDY:
Activity
Toxicity
Selectivity and Specificity
Mechanism Of Action
Drug Metabolism
16. The following types of studies are performed:
PHARMACODYNAMIC STUDIES
Here actions relevant to the proposed therapeutic use are studied.
For e.g., Study of Antihypertensive activity of lead compound.
TEST ON ISOLATED ORGANS,BACTERIAL CULTURES
Performed to detect specific activity such as Antisecretory, Antibacterial.
TEST ON ANIMAL MODELS OF HUMAN DISEASES
17. GENERAL OBSERVATION TEST
Drugs injected in tripling doses to small groups of mice and observed for overt effects.
CONFIRMATORY TEST AND ANALOGOUS ACTIVITIES
Active compounds are taken for detailed study and also tested for other related
activities.
MECHANISM OF ACTION
Attempts are made to find out mechanism of action.
SYSTEMIC PHARMACOLOGY
QUANTIATIVE TESTS
18. TOXICOLOGICAL STUDIES:
Aim : To determine safety of compound in atleast two Animal species by oral and
Parenteral route.
Types :
1) ACUTE TOXICITY
Aim is to find out the acute dose that is lethal to 50% of animals (LD 50)
Organ toxicity is examined by histopathology on all animals.
19. 2) SUBACUTE TOXICITY:
Aim : Identify target organs susceptible to drug toxicity.
Animals maintained at Maximum tolerated doses for 1-3 months to allow development of
pathological changes.
Finally animals are killed and subjected to histopathological examination.
3) CHRONIC TOXICITY:
Important if the drug is intended for chronic use in humans.
Duration of study ranges from one to two years.
20. PHARMACOKINETIC STUDIES
Done after toxicological studies.
Information is obtained about its Pharmacokinetic parameters.
SPECIAL LONG TERM TOXICITY
Test performed only on drugs which cross phase 1 clinical trials.
REPRODUCTION AND TERATOGENICITY
Effects on Spermatogenesis, Ovulation, Fertility and developing foetus are studied.
21. MUTAGENECITY
Ability of the drug to induce genetic damage is assessed in bacteria, Mammalian
cell cultures and intact rodents.
CARCINOGENECITY
Drug is given for long term and observed for development of tumours.
Standardized procedures under “GOOD LABORATORY PRACTICES” (GLP)
are laid down for conduct of animal experiments, especially toxicity studies.
This ensures reliability and reproducibility of laboratory data and minimise
human errors.
22. ASSESSMENT OF SAFETY INDEX
Therapeutic Index.
Maximum tolerated dose.
No observable adverse effects level (NOAEL)
No observable Effects level (NOEL )
Human Equivalent dose (HED) are determined in species similar to humans(like
monkeys) to calculate FIRST IN HUMAN DOSE (FIH) which will be used in phase 1
clinical trials.
FIH is 1/5 or 1/10th of HED.
23. “CLINICAL TRAIL PHASE ( HUMAN TRAILS)”
A Systematic study of a New Drug in human subjects to generate data for
verifying the Pharmacological and adverse effects with an aim to determine the
Safety and Efficacy of the drug in question.
The clinical trails are done under the guideline of Good Clinical Practice
(GCP) laid down by International Conference on Harmonization (ICH) and
Declaration of Helsinki.
Good clinical practice include:
• Protection of human rights as subject in clinical trial.
• Provides assurance of the safety and efficacy of newly developed compounds.
24. The Declaration of Helsinki is a set of ethical
principles regarding human experimentation developed
for the medical community by the World Medical
Association
The Declaration was originally adopted in June 1964 in
Helsinki, Finland, and has since undergone seven
revisions (the most recent at the General Assembly in
October 2013)
25. HISTORY OF CLINICAL TRIAL
World’s First Clinical Trial was recorded in the
BOOK of DANIEL in the BIBLE.
James Lind is Considered the first physician to
have conducted a controlled clinical trial of the
Modern era In 1747
26. WHY CLINICAL TRIALS?
To Discover or Verify:
Pharmacodynamics ( how it works )
Pharmacokinetics ( What happens to it )
Therapeutic effects ( Efficacy)
Adverse Reactions ( Safety )
27. PRECLINICAL NEW DRUG OR
INVESTIGATIONAL NEW DRUG
After the New Compound passes the Pharmacological Screening
The Manufacturer may file a Preclinical New Drug or Investigational New Drug
Application to an authorised Drug Control body of respective country.
In India it is submitted to the Drugs Controller General, Govt of India, New
Delhi.
28. The IND Application must contain the following information about the test drug:
1. Chemical structure, source, its manufacturing data with details of purity.
2. Preclinical data about Pharmacodynamics, pharmacokinetics and toxicology studies
with ED50 and LD50 data.
3. Specification of dosage forms.
4. Detailed description of the investigational protocol to be undertaken.
5. Names and qualifications of each investigator and facilities available to them.
29. 7. Agreement from the sponsors to submit annual progress report regularly.
8. Certificate of Informed consent from human volunteers and that ethics of research
in human beings will be followed.
9. Sponsors has to ensure that copies of all information material has been supplied to
each investigator.
10. Only when approval is given by the regulatory body, the drug can be
administered to the men for clinical trail.
30. ETHICS COMMITTEE AND ITS
RESPONSIBILITIES
The Institutional Ethics Committee (IEC ) ensure
the rights and welfare of the participants in clinical
trails.
Responsibilities:
a) Review and accord its approval to a clinical trail
according to protocol.
b) Safeguard the rights, safety and well being of the
trail subjects.
c) Make a periodical review of the trail and ensure
standard operation procedures (SOPs) and protocols are
followed.
31. INFORMED CONSENT
Law requires that the investigator should obtain the written informed consent from
every human volunteer.
The investigator must provide information about the study verbally as well as by
providing a Patient Information Sheet(PIS) in a language that is understandable by
subjects participating in the trail.
Both the Patient Information Sheet as well as the Informed Consent from should
be approved by the IEC before submitting to the licensing authority.
32. BASIC ELEMENTS OF INFORMED CONSENT
Statement that the study involves research and
purpose of research.
Description of any risks or discomforts.
Description of any benefits to the subjects.
Disclosure of appropriate alternative procedures
or treatment that may be available.
33. Statement describing the extent to which confidentiality of records will be
maintained.
Explanation as to whether any compensation or any medical treatment are
available if injury occurs.
Explanation of whom to contact for answers related to research.
Statement that participation is voluntary.
34. “UNETHICAL TRIAL”
The Tuskegee Syphilis Study was an infamous and unethical
clinical study conducted between 1932 and 1972 by the U.S.
Public Health Service, to observe the natural progression of
Untreated Syphilis in African-American men in Alabama under
the guise of receiving free health care.
35. “CLINICAL TRAIL : PHASES”
PHASE 1
Performed on a small number of healthy volunteers (25-100).
OBJECTIVES:
1)To check for safety and its tolerability.
2) Determine whether humans and animals shows significant Pharmacokinetic
differences.
3)Determine a safe clinical dosage range in humans.
4) Determine the pharmacokinetics of the drug in humans.
5) Detect any predictable toxicity.
These trails are NON BLIND or OPEN LABEL.
36. “PHASE II”
Purpose: Gather evidence that the drug has the effects as suggested by Preclinical trials.
Trials divided into EARLY and LATE PHASES.
EARLY PHASE II
A small number of Patients ( up to 200 ) are studied in detail to observe the potential
therapeutic benefits and side effects.
SINGLE BLIND.
LATE PHASE II
Trials are conducted on large number of patients (200-400).
DOUBLE BLIND.
37. “PHASE III”
Large scale Multicentred randomized Double blind trail.
Conducted in 1000-5000 plus patients.
Done to establish safety and efficacy.
Trails are made using DOUBLE – BLIND CROSS OVER Designs.
38. “NEW DRUG APPLICATION”
Once the Phase III trials are completed.
Sponsors can file a “NEW DRUG APPLICATION” with the Drug Control Authorities
of respective country.
New drug application usually contains thousands of pages and includes complete
detailed monograph of the product, results of the trials, proposed registered name of
product and package insert.
Data is reviewed by Drug Control Authorities and even by outside consultant.
If documentation is in compliance with the regulations, the drug control authorities can
allow the drug to enter the market with NEW DRUG STATUS.
39. “PHASE IV”
It is Post Licensing Phase.
No fixed duration as it is Surveillance phase & Performance of the drug is
monitored for several years.
During the New Drug Status period, the manufacturer is expected to report any
information about the drug concerning its safety.
Such periodic safety update report is to be submitted every 6 months to first 2
years and then annually for the next 2 years.
Drug remain in “New Drug Status” for several years until Drug Control
Authorities are confident about its release to unrestricted marketing.
40. “PHARMACOVIGILANCE”
Greek : Pharmakon = a drug, Vigilare = to be observant means to remain vigilant and observe the adverse
effects of drugs.
Continuous monitoring for unwanted effects and other safety related aspects of marketed drugs.
WHO defines it as the science and activities relating to the Detection, Assessment, Understanding and
Prevention (DAUP) of adverse affects or any drug related problems.
WHO prepared a document on “SAFETY MONITORING OF MEDICINAL PRODUCTS” and suggested
guidelines for setting up and running a pharmacovigilance centre in every country.
ADR data of a new drug ( even of an old drug ) can be shared with global health care community through WHO
Uppsala Monitoring centre located in Sweden.
41. PHARMACOVIGILANCE
PROGRAMME OF INDIA (PvPI)
In the year 2010,the Ministry of Health and Family welfare started a nationwide
Pharmacovigilance Programme by the name Pharmacovigilance Programme of India.
Objectives:
• Monitor ADRs in Indian Population.
• Create awareness about the importance of ADR reporting.
• Monitor benefit risk profile of Medicines approved.
• Generate evidence based recommendations on medicine safety.
• Support CDSCO in formulating safety related regulatory decisions.
• Create a national centre excellence at par with global drug safety
monitoring standards.
42. “EXAMPLES OF DRUG WITHDRAWAL”
Antihistamine :Terfenadine, Astemizole producing “Torsa de
Pointes”
Selective COX-II inhibitor : Rofecoxib and Celecoxib for
producing Cardiotoxicity.
NSAIDs : Nimesulide is banned for all age groups in Western
Countries and for Paediatric age group in India.
Aspirin Liquid Formulation due to possibilities of producing
Reye’s Syndrome in Children.
43. “CLINICAL TRIALS: Recent Developments”
Celltrion is set to launch global Phase 3
clinical trial for its Bevacizumab
biosimilar ‘CT-P16' for the treatment of
cancer.
In July, 2018, I-Mab Biopharma (I-Mab)
announced that it received clinical trial approval
from China National Drug Administration
(CNDA) for TJ103 INJECTION: an
innovative, humanized, long-acting recombinant
glucagon-like peptide-1 (hGLP-1) fused with a
hybrid Fc for TYPE 2 DIABETIS
TREATMENT
44. As per reports of clinicaltrials.gov,
The Number of Clinical Trials in
India is expected to grow by 2018-19
as a result of regulations for clinical
trials in India becoming more stable
and predictable, according to Dr Chirag
Trivedi, President, Indian Society for
Clinical Research (ISCR).
45. “CLINICAL TRIAL DEATHS”
• An RTI response received by NGO
Swasthya Adhikar Manch, reveals that a
Total of 24,117 cases of deaths and SAEs
due to Clinical trials occurred between
January 2005 and September 2016.
• According to the RTI response, 341 cases
of SAEs resulting in death were
reported in 2015, out of which only four
cases were compensated.
47. CONCLUSION
Drug discovery and development process is a long and complicated process.
Before any newly discovered drug is placed on the market, it must undergo extensive
testing.
Advances in understanding human biology and disease are opening up exciting new
possibilities for breakthrough medicine.
At the same time researchers face great challenges in understanding and applying these
advances to the treatment of disease.
Each Success is built on many, many prior failures.